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Triacylglycerol (TAG) is a fat that serves as a vital energy source in eukaryotes. TAG is 
synthesized de novo in the liver and fat cells through a pathway that is initiated by the enzyme 
glycerol-3-phosphate acyltransferase (GPAT) and next catalyzed by acylglycerolphosphate 
acyltransferase (AGPAT). It was hypothesized the deletion of GPAT would result in decreased 
activity in the TAG synthesis pathway and therefore decreased AGPAT activity. To investigate 
this idea, the activity of AGPAT was assayed in tissue homogenates from liver and adipose of 
mice lacking GPAT3 or GPAT4, the main GPAT isoforms. Contrary to the hypothesis, AGPAT 
activity was elevated in GPAT3-deficient and GPAT4-deficient liver samples and adipose 
samples compared to those prepared from wild type mice. This result suggests the activity of 
the TAG synthesis pathway increases to compensate for the absence of the rate limiting 
enzyme, GPAT. In addition to AGPAT’s responsiveness to GPAT, the sub-cellular localization 
of AGPAT was also explored. AGPAT was known to localize to the ER membrane, but it is 
hypothesized that the ER shares membranes with lipid droplets, the organelles that store TAG. 
Thus, we predicted that AGPAT activity would be detectable in isolated lipid droplets. AGPAT 
activity was measured in lipid droplet and microsomal fractions of murine wild type, GPAT3-
deficient and GPAT4-deficient livers. AGPAT activity was indeed detected in the lipid droplet 
fraction, supporting our hypothesis that the ER membranes are contiguous with lipid droplets. 
AGPAT activity was higher in lipid droplet and microsomal fractions in GPAT3-deficient tissues 
compared to wild type mice, consistent with our results above and suggesting a general 
cellular response to the absence of a major GPAT isoform. Understanding the functions and 
interactions of the enzymes along the TAG synthesis pathway can provide insights that will 
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inform the development of treatments for metabolic conditions such as heart disease, obesity, 
and diabetes, in which it is desirable to control TAG synthesis. 
Introduction: 
Triacylglycerol (TAG) is a vital energy source in every eukaryote. In mammals, TAG is 
most abundantly produced in specialized cells called adipocytes, which are found in 
subcutaneous fat deposits, around internal organs, and within muscles [1][2]. Lipid droplets are 
organelles within cells that store TAGs, influence hormone storage and signaling, and regulate 
the production and breakdown of fats [3]. Lipid droplets and the enzymes in the glycerolipid 
pathway are instrumental in regulating fat production and breakdown, yet the interactions 
between lipid droplets, membrane proteins, and other organelles are not well understood. 
Metabolic pathologies, such as obesity, cardiovascular disease, and diabetes share a common 
factor: aberrant fat synthesis or oxidation. Understanding the interactions, movement, and 
expression of proteins in the TAG biosynthetic pathway could lead to new treatments for heart 
disease, insulin resistance, and obesity. 
Figure 1: Pathway of de novo TAG production. Circles indicate an intermediate compound and 
arrows indicate an enzyme [6]. 
The glycerol-3-phosphate acyltransferase (GPAT) enzyme catalyzes the first step in 
TAG production: glycerol-3-phosphate (G3P) is esterified to lysophosphatidic acid (LPA). The 
second step is catalyzed by the acylglycerolphosphate acyltransferase (AGPAT) enzyme, 
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which acylates LPA to become phosphatidic acid (PA). Lipin removes the phosphate group on 
PA, leaving a hydroxide group and producing diacylglycerol (DAG). Diglyceride acyltransferase 
(DGAT) acylates DAG to produce TAG. Two isoforms of the GPAT enzyme, GPAT3 and 
GPAT4, are located in the endoplasmic reticulum (ER) membrane and account for 50-70% of 
the GPAT activity in the liver and up to 90% in most other tissues [6]. GPAT enzymes have 
garnered greater scientific inquiry than AGPAT enzymes because they perform the initial and 
rate-limiting step of TAG synthesis, leaving AGPAT enzymes comparatively understudied [6]. 
Eight AGPAT isoforms have been identified, but only the ER membrane-bound AGPAT1 and 
AGPAT2 have been comprehensively studied [6]. This study examines AGPAT enzyme activity 
in murine liver in the absence of GPAT3 or GPAT4 to elucidate the relationship between the 
AGPAT, GPAT3, and GPAT4 enzymes. Because the absence of GPAT4 results in a 45-50% 
decrease of TAG in murine liver compared to wild type mice [6], it is predicted AGPAT activity 
will also be decreased in the absence of GPAT4. Since GPAT3 and GPAT4 are both major 
isoforms of GPAT [4][6], it is also predicted that AGPAT activity will be decreased in GPAT3 
knockout murine tissues. 
    In addition to the relationship of the AGPAT and GPAT enzymes, the possible subcellular 
localization of AGPAT to fat storage organelles will also be investigated. Absence or mutation 
of the enzymes in the TAG synthesis pathway may result in abnormal or absent fat production 
and common metabolic conditions such as insulin resistance and fatty liver disease [4][6]. 
Surplus lipid storage by the lipid droplets within cells is linked to related metabolic conditions 
such as obesity and diabetes [3]. The scientific community has regarded lipid droplets as 
inactive collections of lipids until recently, and therefore their functions as dynamic organelles 
are not well characterized. The relationship between lipid droplets, their associated proteins, 
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and their interactions with other organelles are also not well understood [3]. The ER budding 
model proposes that the ER membrane and integral proteins are incorporated into lipid 
droplets [3]. To investigate the localization of AGPAT, the enzyme’s activity is measured in 
isolated lipid droplets and isolated microsomes of GPAT3-/-, GPAT4-/-, and wild type mice. 
Because the major AGPAT isoforms are normally embedded in the ER, detection of AGPAT 
activity in the isolated lipid droplets would suggest the ER had shared membrane and integral 
proteins with the lipid droplets. It is predicted AGPAT enzyme activity will be detected in 
isolated murine lipid droplets, supporting the ER budding model’s prediction that lipid droplet 
and ER membranes are continuous.  
    Understanding the biological links between lipid droplets, GPAT, and AGPAT could inform 
treatments for heart disease, diabetes, and obesity. Measuring the activity of GPAT and 
AGPAT enzymes in each genotype increases understanding of the greater network of these 
enzymes’ interactions and functions. This project will explore AGPAT activity in the liver and 
adipose tissues, as well as microsomal and lipid droplet fractions, of GPAT3 knockout, GPAT4 
knockout and wild type mice. 
Methods: 
Sample Preparation: Total membrane particulates were prepared from the livers or adipose 
tissue of mice from each genotype as described by Wendel et al. [5]. Lipid droplet fractions and 
microsomal fractions were prepared by pooling three mouse livers from mice of each 
genotype. 
BCA Assay: The concentration of protein in each total particulate sample was determined 
through a bicinchoninic acid assay (BCA) using Pierce™ BCA Protein Assay Kit.  
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Enzyme Activity Assay: A radiometric enzyme activity assay was used to determine the activity 
of the AGPAT enzyme in liver and adipose total particulates, or lipid droplet and microsomal 
fractions of GPAT3-/- and GPAT4-/- mice, as well as wild-type controls. AGPAT activity was 
calculated by measuring the amount of radiolabeled PA product formed per milligram of protein 
per minute.  The enzyme activity assay for AGPAT was prepared with 119 μL AGPAT mix (100 
mM Hepes NaOH pH 7.5, 200 mM NaCl, 5% glycerol, 50 μM 16:0 CoA, 20 μM [3H] oleoyl LPA, 
1 mg/mL BSA, 8 mM NaF, 10 mM EDTA, 1 mM DTT). Enough water was added for the final 
volume of each reaction to be 200 μL. The 16:0 palmitoyl CoA functions as the acyl donor for 
the conversion of tritium [3H] labeled LPA to [3H]-PA, to be measured and quantified. 
Medium I (250 mM sucrose, 10 mM Tris buffer pH 7.5, 1 mM EDTA) was combined with 
protease and phosphatase inhibitors and was used to dilute the protein sample to 0.25 mg/ml. 
The reaction was initiated by the addition of either 5, 10, or 15 μg of protein to the AGPAT mix 
and proceeded for 5 min. The reaction was stopped with 600 μL of 1% perchloric acid and 3 
mL of chloroform: methanol (1:2, v/v).   
Lipid Extraction: The samples sat for 5 min at room temperature, and then the phases were 
broken by the addition of 1 mL of 1% perchloric acid and 1 mL of chloroform. The samples 
were centrifuged for 5 min at 3,000 rpm at 4°C. Next, the upper phase was aspirated and the 
remaining solvent was washed with 2 mL 1% perchloric acid. Each sample was vortexed. The 
samples were centrifuged again with the same settings, and the upper phase was aspirated 
again. The second wash used 2 mL of 1% perchloric acid. After being vortexed again, the 
samples were centrifuged for the third time at the same setting. The upper phase was 
aspirated once more. One mL of the solvent phase containing the extracted lipids was dried in 
a Speedvac concentrator. After drying, the samples were stored at -20 °C. 
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Thin Layer Chromatography: Dried lipid extracts were resuspended in 50 μL of 2:1 chloroform: 
methanol (v/v). A 20-channel silica thin layer chromatography plate was washed with acetone 
and air dried before spotting. Each resuspended sample was spotted onto a well. Next, 10 μL 
of PA standard were spotted in each lane (5 mg/ml, 1,2-dioleoyl-G3P, Avanti). The plate was 
developed using an 88% formic acid: pyridine: chloroform (7:30:50, v/v/v) solvent system. After 
drying, the plate was sprayed with 0.05 mg/ml primuline and the PA standard was visualized 
using UV light. Each sample was scraped from the TLC plate into a scintillation vial with 4 mL 
of EcoLite (MP Biomedicals, scintillation cocktail). Two scintillation vials were prepared with 4 
mL of EcoLite and 10 μL of 200 μM [3H]1-oleoyl-LPA to calculate the specific activity. The 
decay rate of the [3H]-label in each sample was counted using a Wallac L5C 1409 liquid 
scintillation counter. 
Results 
AGPAT Activity is Higher in GPAT3 and GPAT4 Knockout Mice Compared to Wild Type 
It is known TAG levels are 45-50% lower in the livers of GPAT4 knockout mice 
compared to wild type mice [6]. It is logical that GPAT activity declines when a major GPAT 
isoform is absent, but it is not known how AGPAT activity adjusts to the deficiency of the rate 
limiting enzyme. It was predicted that AGPAT activity would be decreased in GPAT3 and 
GPAT4 knockout mice compared to wild type. AGPAT enzyme activity was assayed in the liver 
total particulate and adipose total particulate of wild type, GPAT3 knockout, and GPAT4 
knockout mice.  
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Figure 2: AGPAT activity is higher in the liver and adipose total particulate of either GPAT3 or 
GPAT4 knockout mice, compared to wild type. For all genotypes, n=3. Error bars represent +/- 
SD. 
Wild type mice showed significantly lower AGPAT enzyme activity in the liver total 
particulate and adipose total particulate than the knockout mice in the respective tissue 
samples (Figure 2). In all three genotypes, enzyme activity was lower in the adipose tissue 
than in liver tissue of the same genotype. AGPAT activity is higher in GPAT3 and GPAT4 
knockout murine tissues compared to wild type, in contrast to the prediction. 
AGPAT Activity was Detected in Isolated Lipid Droplets, in Agreement with ER Budding 
Hypothesis 
AGPAT was previously found to localize to the ER [6], but it was hypothesized that the 
ER may share membranes with lipid droplets [3]. In the next experiment, the enzyme activity 
assay was used to investigate the cellular localization of AGPAT. Differential centrifugation 
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was used to prepare microsomal and lipid droplet fractions from livers of wild type, GPAT3 
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Figure 3: AGPAT enzyme activity was detected in the lipid droplet fractions of wild type, 
GPAT3 knockout and GPAT4 knockout mice. For each genotype, n=1. 
AGPAT enzyme activity was assayed in lipid droplets and microsomes of mice. 
Fractions were prepared by differential centrifugation of a pool of three mouse livers for each 
genotype. Specific AGPAT activity was higher in the microsomes than the lipid droplets across 
all three genotypes. GPAT3 knockout mice had higher microsomal and lipid droplet AGPAT 
activity than wild type and GPAT4 knockout mice. Lipid droplets from wild type mice had the 
lowest AGPAT activity. It was predicted that AGPAT activity would be detected in the isolated 




The initial rate enzyme assay measures the quantity of product an enzyme can produce 
over a given amount of time. The assay provides a reaction environment unlike that of a cell. 
The enzyme is presented with functionally unlimited substrate in an environment optimized for 
temperature, pH, and salt content. By definition, in an initial rate enzyme assay, the enzyme 
converts substrate to product at a maximal rate as a result of the ideal reaction conditions. 
Consequently, the assay does not measure the absolute activity of the enzyme in vivo, but is a 
reproducible method of determining relative activity of the target enzyme under the 
experimental conditions, such as the differing tissue types or mouse models. Since not every 
AGPAT enzyme will be active during the assay, an elevated specific activity does not denote a 
higher concentration of AGPAT enzyme, rather a higher rate of PA production by the enzymes 
present in the sample cells given the experimental conditions. 
AGPAT enzyme activity is higher in GPAT3 or GPAT4 knockout mice, both in liver 
tissue and in adipose tissue, compared to wild type mice (Figure 2). Hepatic TAG levels are 
45-50% lower in GPAT4 knockout mice compared to wild type mice [6]. Because the absence 
of GPAT4 resulted in decreased net TAG production, it was predicted AGPAT activity would 
also be decreased in GPAT4 knockout mice. Since GPAT3 and GPAT4 together constitute 50-
70% of GPAT activity in the liver and 90% in other tissues [4][6], it was predicted that the net 
TAG production in the absence of GPAT3 may resemble the decreased TAG production in the 
absence of GPAT4. Therefore, it was also predicted that AGPAT activity would be decreased 
in GPAT3 knockout mice compared to wild type mice. When assessing AGPAT enzyme 
activity in GPAT3 knockout mice, it is important to consider that GPAT3 has been reported to 
have AGPAT activity [7], which may lead to an inaccurately low measurement of AGPAT 
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activity in its absence. Higher AGPAT activity in GPAT3 knockout and GPAT4 knockout mice 
compared to wild type mice suggests the overall decrease of TAG in GPAT4 knockout mice is 
not a direct result of decreased activity in the production pathway. AGPAT activity may be 
higher in GPAT3 and GPAT4 knockout mice because a feedback mechanism notifies the cell 
of decreased GPAT activity and attempts to correct for the lower amount of LPA, perhaps, by 
upregulating AGPAT. It is also possible that in the absence of GPAT3, regulatory mechanisms 
notify the cell of decreased GPAT activity and so the cell upregulates GPAT4, or another 
GPAT isoform, to compensate. In GPAT3 knockout mice, it is possible that GPAT4 is 
compensating and producing more LPA than in wild type mice, and likewise with GPAT3 in 
GPAT4 knockout mice. A complementary experiment should measure GPAT3 and GPAT4 
mRNA transcripts in each knockout mouse to determine relative transcription levels and use 
western blotting to determine the expression levels of each protein isoform in the absence of 
the other. GPAT3 and GPAT4 transcripts and protein quantities should also be measured in 
wild type mice as a control. 
Wild type, GPAT3- and GPAT4- knockout mice had higher AGPAT specific activity in 
microsomes than in lipid droplets (Figure 3). This finding is reasonable considering 
microsomes are composed of ER and AGPAT is embedded in the ER membrane [6]. GPAT3 
knockout mice had the highest AGPAT activity in both lipid droplets and microsomes, while 
wild type mice had the lowest AGPAT activity in lipid droplets. The observation that GPAT3 
knockout mice had higher AGPAT activity in both fractions (Figure 3) supports the ER budding 
hypothesis, which proposes that the ER membrane and integral proteins are incorporated into 
lipid droplets [3]. AGPAT, which is embedded in the ER membrane, could be transferred to the 
lipid droplet with the movement of the ER membrane phospholipids. If membrane sharing 
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between the ER and the lipid droplets is similar among GPAT3 knockouts, GPAT4 knockouts, 
and wild type mice, then greater AGPAT activity in the ER membrane would lead to a 
proportionally greater activity in the lipid droplet. For example, if GPAT3 knockout mice had 
more active AGPAT in the microsomes, and all genotypes share membrane between the ER 
and lipid droplets at similar rates, then proportionally more AGPAT enzyme activity would be 
detectable as the enzyme was sent from the ER to the lipid droplets compared to other 
genotypes. The AGPAT activity in the lipid droplets of wild type and GPAT4-deficient mice was 
low but detectable (Figure 3). To agree with the lipid budding hypothesis, one genotype would 
have to have displayed the lowest AGPAT activity in both fractions. However, wild type mice 
have the lowest AGPAT expression in lipid droplets while GPAT4 mice have the lowest activity 
in the microsomes out of the three genotypes. The AGPAT activity in the lipid droplets of wild 
type and GPAT4 knockout mice are nearly identical and relatively low, so a larger sample size 
should be assayed to determine if a pattern between relative AGPAT activity in the 
microsomes and lipid droplets exists.  
In contrast to the prediction, AGPAT activity was higher in GPAT3 and GPAT4 
knockout mice compared to wild type mice (Figure 2). The higher AGPAT activity suggests a
possible cellular response to compensate for the missing GPAT isoform. Western blotting can 
be used to confirm suspected overproduction of the AGPAT enzyme in GPAT3- and GPAT4-
knockout mice. Determining how the TAG synthesis pathway is regulated is instrumental in 
understanding pathologies such as insulin resistance. 
 AGPAT activity in lipid droplet fractions implies that the enzyme is present in the lipid 
droplets of murine liver cells. The correlation between increased AGPAT activity in the lipid 
droplets and microsomes of GPAT3 knockout mice agrees with the hypothesis that AGPAT 
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may be transferred from the ER to the lipid droplets by membrane budding. The data garnered 
in this project is important in making progress toward a full understanding of fat production and 
regulation. Elucidating the workings of the proteins involved in TAG synthesis is necessary for 
developing treatments of prevalent ailments, including diabetes, obesity, lipodystrophy, and 
heart disease. 
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